Trump closes first round of drug price negotiations with Regeneron deal

President Trump announced a significant drug pricing agreement with Regeneron on Thursday, marking the final deal of the 17 agreements that were initially pursued by the White House last year. This agreement with Regeneron includes a commitment to reduce drug prices for Medicaid, offer the cholesterol medication Praluent on TrumpRx for $225, and invest a substantial $27 billion in drug development within the United States.

In addition to this pricing agreement, Regeneron also made headlines on the same day with the Food and Drug Administration’s approval of Otarmeni. This gene therapy is the first of its kind to receive approval under the FDA’s new National Priority Voucher program. In clinical trials, Otarmeni has shown promising results in providing modest hearing improvements for individuals with a rare form of hearing loss. However, it is important to note that the development of this drug has faced criticism from certain segments of the Deaf community.

Regeneron has pledged to make Otarmeni available to American patients at no cost, further demonstrating their commitment to innovation and accessibility in healthcare. This move is expected to have a significant impact on individuals struggling with hearing loss and could potentially pave the way for future advancements in gene therapy treatments.

Overall, the drug pricing agreement and the approval of Otarmeni highlight Regeneron’s dedication to research and development in the pharmaceutical industry. These developments also underscore the importance of collaboration between government entities and private companies in advancing healthcare solutions for the benefit of all Americans.